文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

玻璃体腔注射康柏西普治疗早产儿视网膜病变后的全身药代动力学与VEGF药效学

Systemic conbercept pharmacokinetics and VEGF pharmacodynamics following intravitreal injections of conbercept in patients with retinopathy of prematurity.
PubMed 文献 · Br J Ophthalmol · 2021-04-09

结果显示,注射后1周血清VEGF显著低于基线,4周时回升至基线水平;血清康柏西普在1周时为19.81±7.60 ng/mL,基线及4周时均低于定量下限。

要点

  • IVC后1周血清VEGF较基线显著下降,4周时回到基线水平。
  • 血清康柏西普1周时为19.81±7.60 ng/mL,基线与4周均低于定量下限。

核心结论

  • 玻璃体腔注射康柏西普后1周血清VEGF显著低于基线,但4周时恢复至基线水平。
  • 血清康柏西普在1周时升高,至4周时低于定量下限。

研究设计与样本

  • 所有婴儿双眼均接受治疗,其中一眼注射康柏西普0.25 mg/0.025 mL,随访至少6个月。
  • 在IVC前及IVC后1周、4周采集血样,主要结局指标为血清康柏西普与VEGF浓度。

主要发现

  • 基线、IVC后1周、4周的血清VEGF分别为953.35±311.90 pg/mL、303.46±181.89 pg/mL、883.12±303.89 pg/mL。
  • IVC后1周血清VEGF显著低于基线(p<0.05),4周时显著高于1周(p<0.05)。
  • 基线与该研究4周时血清VEGF差异无统计学意义(p>0.05)。
  • 血清康柏西普在基线及4周时低于定量下限(BLOQ),1周时为19.81±7.60 ng/mL。

关键数值与推荐

  • 血清VEGF:基线953.35±311.90 pg/mL,1周303.46±181.89 pg/mL,4周883.12±303.89 pg/mL。
  • 血清康柏西普:基线BLOQ,1周19.81±7.60 ng/mL,4周BLOQ。
  • 统计学比较:1周vs基线p<0.05,4周vs 1周p<0.05,4周vs基线p>0.05。

临床怎么用

  • 提示IVC后1周全身VEGF受抑制、4周时恢复,临床随访可关注这一时间窗。
  • 血清康柏西普1周可检出、4周低于定量下限,可供评估全身暴露参考。

局限性

  • 仅报告至IVC后4周的血样结果,随访至少6个月但摘要未报告更长期药代数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on serum vascular endothelial growth factor (VEGF) and drug levels in patients with retinopathy of prematurity (ROP) following intravitreal injections of conbercept (IVC) are lacking. METHODS: Multicentre, prospective, non-randomised study of patients with aggressive posterior retinopathy of prematurity (APROP) or type 1 ROP who had not received other treatment. All infants received therapy in both eyes plus intravitreal IVC 0.25 mg/0.025 mL in one eye and had at least 6 months of follow-up. Blood samples were collected before and 1 week and 4 weeks after IVC. The main outcome measures were serum conbercept and VEGF concentrations. RESULTS: Forty infants with APROP or type 1 ROP were enrolled. The mean serum VEGF at baseline and 1 week and 4 weeks after a total of 0.25 mg of IVC was 953.35±311.90 pg/mL, 303.46±181.89 pg/mL and 883.12±303.89 pg/mL, respectively. Serum VEGF 1 week after IVC was significantly lower (p<0.05) than baseline, and at 4 weeks after IVC, it was significantly higher (p<0.05) than at 1 week. There was no significant difference (p>0.05) between baseline and 4 weeks. Serum conbercept was below the limit of quantitation (BLOQ) at baseline and 4 weeks and was 19.81±7.60 ng/mL at 1 week. CONCLUSION: Serum VEGF 1 week after IVC was significantly lower than baseline but returned to baseline at 4 weeks. Serum conbercept increased at 1 week and was BLOQ at 4 weeks.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Cheng Y, Sun S, Deng X, et al. Systemic conbercept pharmacokinetics and VEGF pharmacodynamics following intravitreal injections of conbercept in patients with retinopathy of prematurity. Br J Ophthalmol. 2021. PMID: 33836990. doi:10.1136/bjophthalmol-2021-319131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。